Immune cell engager therapy for brain cancer
Open Access
- 18 September 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
Abstract
Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first-line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumors advance and metastasize, prompting the need for new treatment modalities. Recent innovations in antibody-based immunotherapies may complement brain cancer treatment. Biotechnical engineering platforms yield new antibody-inspired biomolecules for optimal engagement of specific and tumor-associated antigens, which also recruit and elicit immune effector cell functions. Here, we review current advances on multi-specific immune cell engagers for brain tumor treatment and provide novel insights into overcoming existing challenges.Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (#02103266)
- European Molecular Biology Organization
This publication has 132 references indexed in Scilit:
- Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapyClinical and Translational Medicine, 2024
- Focused ultrasound-mediated enhancement of blood–brain barrier permeability for brain tumor treatment: a systematic review of clinical trialsJournal of Neuro-Oncology, 2024
- CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomasScience China Life Sciences, 2024
- Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomideJournal of Neuro-Oncology, 2024
- The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor typesCancer, 2020
- Emerging functions of the EGFR in cancerMolecular Oncology, 2017
- Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiformeJournal of Neuro-Oncology, 2017
- Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer CellsTargeted Oncology, 2015
- Cellular immune surveillance of central nervous system bypasses blood–brain barrier and blood–cerebrospinal–fluid barrier: Revealed with the New Marburg cerebrospinal–fluid model in healthy humansCytometry Part A, 2015
- Interleukin‐13 receptor α2 chainCancer, 2006